A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance

Current evidence indicates that resistance to the tyrosine kinase-type cell surface receptor (HER2)-targeted therapies is frequently associated with HER3 and active signaling via HER2-HER3 dimers, particularly in the context of breast cancer. Thus, understanding the response to HER2-HER3 signaling a...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Akhrass, Hussein, Conway, James R. W., Poulsen, Annemarie Svane Aavild, Paatero, Ilkka, Kaivola, Jasmin, Padzik, Artur, Andersen, Olav M., Ivaska, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892347/
https://www.ncbi.nlm.nih.gov/pubmed/33420373
http://dx.doi.org/10.1038/s41388-020-01604-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892347/
https://www.ncbi.nlm.nih.gov/pubmed/33420373
http://dx.doi.org/10.1038/s41388-020-01604-5

Ejemplares similares